8
Years of research
A new standard for longevity supplements
Most companies sell supplements. NOVOS runs a longevity research program.
Thousands of products call themselves longevity supplements. But an ingredient affecting one molecule or one biomarker does not by itself demonstrate meaningful support for how the body ages.
NOVOS Core was designed as a coordinated system targeting the 12 Hallmarks of Aging, then investigated through mechanistic studies, aged-animal models and human clinical research.
Mechanistic studies. Animal models. Placebo-controlled human research.
Clinical research validated that NOVOS Core provides nutritional support for biological systems predictive of lifespan and healthspan.
NOVOS CORE
12 ingredients.
12 Hallmarks of Aging.
One coordinated formulation.
7
SCIENTISTS + MDS FORMULATED
7
WHOLE FORMULATION STUDIES
950+
Ingredient studies
2,000+
MDS & CLINICIANS RECOMMEND
15M+
NOVOS servings
Available at
MAYO CLINIC STORE
Bumrungrad International HospitalErewhonEquinoxRemedy PlaceFour SeasonsSunLife Organics
Member of & selected for
Longevity Biotechnology AssociationHealthy Longevity Medicine SocietyXPRIZE Top 100 Healthspan Competition
Third-party tested. Retail availability does not imply institutional medical endorsement.
Why Core is different
Aging doesn’t happen in one place.
The supplement industry sells aging as a single switch.
Scroll social media and the story is always the same: your mitochondria are the problem. Or your stem cells. Or DNA damage. Or senescent cells. Take this one collagen powder, this one peptide, this one miracle molecule, and the effects of aging simply disappear.
It is a compelling pitch because it is simple. It is also wrong. Each of these interventions touches one real piece of biology, and leaves the rest of the aging process untouched.
Tap a strategy. Only one part of the cell lights up. The rest of aging keeps going without it.
Useful biology?
Yes.
The whole aging process?
Not even close.
Calling something a "longevity supplement" does not make it one.
A molecule can change.
That tells us biology was affected, but not if it will impact healthspan or lifespan.
A biomarker can change.
That tells us a measurable signal changed, but not whether it will impact healthspan or lifespan.
Someone can feel different.
That tells us about subjective experience, but not whether their aging slowed or health improved.
But longevity is a bigger question.
CELLS
Did we impact the processes that cause aging?
ANIMAL MODELS
By impacting those processes, were we able to extend animal lifespan and healthspan?
HUMAN PHYSIOLOGY
Were we able to improve organ function in humans that's associated with healthspan and lifespan?
NOVOS investigates all three.
NOVOS Core is a rigorously studied longevity formula, rare in the dietary supplement market.
NOVOS is the only dietary supplement company that is a member of the Longevity Biotechnology Association.
The evidence journey
What has actually been studied?
Cells
Mechanistic research
- Genomic stability
- Cellular senescence signaling
- Stress resilience
- Healthy inflammatory response
Aged animals
Lifespan and healthspan research
- The complete Core formulation has been evaluated in aged-animal research involving lifespan and functional health, with successful results.
Human biological aging
Preliminary epigenetic research
- NOVOS Core + NOVOS Boost
- Statistically significant reduction in DunedinPACE pace of aging measurement
Placebo-controlled human clinical research
Functional physiology
- Improvements in: 1. Endothelial function
- 2. Arterial flexibility
- 3. Healthy blood pressure support
The first human system we measured
Why start with cardiovascular aging?
Cardiovascular function is one of the most consequential systems to preserve as we age.
Blood vessels become less flexible. Endothelial function can decline. Blood pressure tends to rise.
These changes are part of the physiology of aging, even before disease is present.
And the cardiovascular system does not operate in isolation.
It supplies oxygen and nutrients to nearly every tissue in the body, from the brain and muscles to the kidneys, skin and other organs.
That made cardiovascular function a powerful first place to ask a larger question:
Can NOVOS Core's unique approach of targeting the 12 Hallmarks of Aging measurably support a major physiological system that changes with age?
It changes with age
Vascular function changes over time.
With age, arteries tend to become less flexible and endothelial responsiveness can decline.
Blood pressure also commonly rises across adulthood.
These are measurable changes in physiology, which makes the cardiovascular system highly relevant to healthy-aging research.
The whole body depends on it
Every organ depends on circulation.
The cardiovascular system delivers oxygen, nutrients and hormonal signals, and helps transport metabolic products throughout the body.
Healthy circulation therefore supports much more than the heart. It supports the environment in which cells and organs throughout the body function.
You cannot separate cardiovascular health from whole-body health.
The stakes are high
Cardiovascular disease is the #1 cause of age related decline and death.
Cardiovascular disease remains the leading cause of death worldwide, and risk rises substantially with age.
That makes cardiovascular physiology more than a convenient biomarker.
It is one of the most consequential systems to understand and preserve across the lifespan.
Cardiovascular aging is aging.
One important system within a much broader aging process, and one of the clearest places to measure whether that process is being supported.
Foundational infrastructure
Cardiovascular function is foundational infrastructure for the whole body.
Whole body
Every tissue sits downstream of circulation. Cardiovascular function is foundational infrastructure for the whole body.
Illustrative of normal circulatory physiology. No organ-specific disease claims are made.
That is why cardiovascular function was the first system we tested in humans.
It changes meaningfully with age.
It affects the health of virtually every organ.
It has enormous consequences for long-term health.
And importantly for a clinical study, it can be measured using validated functional endpoints.
Endothelial function
How well blood vessels respond when increased blood flow is required.
Arterial flexibility
How elastic the large arteries are, critical for cardiovascular health.
Healthy blood pressure
Whether pressure can be improved starting from within a healthy range.
Cardiovascular function was the first major physiological system we measured in humans. It was not the only system NOVOS Core was designed to support.
Core was designed around the broader biology of aging and the 12 Hallmarks of Aging.
The cardiovascular study gave us something especially valuable:
a way to test whether that upstream formulation approach could produce downstream measurable effects on human physiology.
From signals to function
We wanted to measure more than a biomarker.
Many studies show that a molecule or laboratory marker changed. That can be scientifically useful.
But for NOVOS Core, we also wanted to know something more consequential: did an important physiological system actually function differently?
Biological signal
Indirect / molecular measurement
A biological signal changed.
- NAD+
- Metabolites
- Molecular biomarkers
These measurements can tell us that biology has changed. But they do not always tell us whether an organ or physiological system is functioning better.
Useful. Important. But one layer of evidence.
Physiological function
Direct / functional measurement
The system itself functioned differently.
- Endothelial function
- Arterial flexibility
- Healthy blood pressure
A blood vessel can dilate differently. An artery can transmit a pressure wave differently. Blood pressure can change. These measurements assess how the cardiovascular system actually performs.
That is a much higher bar.
NOVOS Core was not evaluated only by asking whether a molecule moved. We measured whether a major aging-related physiological system functioned differently in humans.
Core was tested at both levels, and the randomized human study focused on functional physiology.
- 6 months
- Randomized
- Double blind
- Placebo controlled
- Adults 40+
RANDOMIZED HUMAN RESEARCH
We tested the complete NOVOS Core formula.
6 MONTHSRANDOMIZEDDOUBLE BLINDPLACEBO CONTROLLEDADULTS 40+
In a six-month randomized, double-blind, placebo-controlled human study, NOVOS Core demonstrated beneficial effects over placebo on multiple functional biomarkers used in aging and cardiovascular research.
Human clinical data is the strongest form of validation, and its meaning deepens when multiple independent measures point in the same positive direction.
Publication status: manuscript under peer review at the time of writing.
The complete finished formula that is available for purchase is what was tested.
Three human results
What the study measured in humans.
Endothelial function
FMD
+2.9 percentage points
Versus placebo.
Support for healthy vascular responsiveness
Flow-mediated dilation measures how effectively an artery expands when blood flow increases.
In published research, each 1% improvement in FMD has been associated with better cardiovascular outcomes in observational populations. A 2.9% change is considered a substantial magnitude in the FMD literature.
FMD effect size vs. lifestyle interventions
NOVOS Core2.9
Resistance training2.11
Mediterranean diet1.3
Aerobic exercise1.2
Severe weight loss1.1
Values shown as % improvement, from published studies in similar adult populations.
Provides support for healthy endothelial function.
Randomized, double-blind, placebo-controlled human research. Outcomes reflect physiological biomarkers rather than disease outcomes. Results should be interpreted in the context of the studied population and full protocol. Individual results vary. Comparisons to lifestyle interventions are not head-to-head: they come from distinct, independent studies with different protocols and populations. NOVOS does not claim that NOVOS Core is superior to healthy lifestyle modifications, which remain foundational to cardiovascular health.
One formula.
Three independent vascular measures.
Randomized human evidence.
The first of its kind dietary supplement to have documented positive and simultaneous effects on endothelial function, arterial flexibility, and healthy blood pressure already within the normal range.
These results are uncommon in dietary supplement research.
Systematic literature benchmark
How unusual were the NOVOS Core cardiovascular results?
Rather than compare Core against a handful of convenient studies, NOVOS reviewed the randomized clinical literature for commonly marketed heart-health supplement ingredients.
Positive results counted. Null results counted too.
How often did published supplement trials produce effects as large and as broad as NOVOS Core?
Separate published trials. Not direct head-to-head randomization.
We started with 3,388 published records.
3,388PubMed records identified
3,384Records screened
147Qualifying randomized controlled trials
142Unique competitor studies
171Study-marker comparisons
55 like-for-like fasted comparisons
36
Blood pressure
8
Arterial flexibility
11
Endothelial function
37
Statistically significant qualifying trial results
110
Null qualifying trial results
Null studies were not thrown away.
A supplement literature review can look much more impressive if only successful studies are shown. This benchmark retained qualifying null results as well as significant results.
How were studies selected?
- Population
- Apparently healthy adults, with the permitted inclusion rules defined by the methodology.
- Intervention
- A single supplement ingredient or its standard forms.
- Control
- Placebo or inert control.
- Outcome
- At least one of systolic blood pressure, arterial flexibility or endothelial function.
- Analysis
- Placebo-adjusted between-group effects.
- Inclusion
- Statistical significance did not determine whether a qualifying study entered the database. Both positive and null evidence was included.
Why compare fasted measurements?
Meals can temporarily influence vascular tone, blood flow and blood-pressure measurements. The NOVOS Core sustained measurements were taken fasted.
For the strictest like-for-like comparison, competitor results also had to be measured under fasted conditions. This produced the 55-comparison primary benchmark.
Same measurement context. Tougher comparison.
This does not eliminate every source of cross-study variability.
Across like-for-like trials, Core set an unusually high bar.
BLOOD PRESSURE
Outperformed
94%
34 of 36 fasted comparisons
Arterial flexibility
Outperformed
100%
8 of 8 fasted comparisons
Endothelial function
Outperformed
64%
7 of 11 fasted comparisons
96%
across the complete 171-comparison database
Outperforms most single-ingredient supplements on every major vascular aging marker.
Separate published trials. Not direct head-to-head randomization.
What counts as outperformance?
For this benchmark, Core exceeded a competitor comparison when the competitor:
- did not demonstrate a statistically significant effect, or
- demonstrated a statistically significant effect smaller than the Core benchmark.
A competitor counted as exceeding Core only when it demonstrated a statistically significant effect larger than Core under the applicable comparison conditions.
This is the benchmark methodology. It is not a direct clinical trial comparing products in the same participants.
On arterial flexibility, Core led every comparison we found.
Even when the fasting restriction was relaxed for competitors.
NOVOS Core1.18 m/s
Magnesium1.00 m/s
Omega-30.20 m/s
Beetroot / nitrateNS
L-ArginineNS
GarlicNS
Orange is NOVOS Core. Green is a statistically significant competitor result. Light gray means no statistically significant demonstrated effect (NS). This wider arterial-flexibility comparison includes both fasted and non-fasted competitor trials.
12 of 12
arterial-flexibility comparisons surpassed
NOVOS Core helped support healthy arterial flexibility, which is rare for a dietary supplement.
Pressure wave travels differently through compliant arteries. Pulse wave velocity provides a functional measure of arterial flexibility. Lower values indicate a more favorable result.
No two people react precisely the same way to nutritional interventions. Individual results will vary, with some obtaining no benefit. Comparisons use results from separate published trials involving different populations and protocols. They are not direct head-to-head randomized comparisons.
How did Core compare with the average published result?
Healthy blood pressure
NOVOS Core6.10 mmHg
Average published result2.53 mmHg
2.4x
Arterial flexibility
NOVOS Core1.18 m/s
Average published result0.43 m/s
2.7x
Endothelial function
NOVOS Core2.90 pp
Average published result2.44 pp
1.2x
Strong across all three, not just one.
These averages come from separate randomized studies involving different participants and protocols.
No two people react precisely the same way to nutritional interventions. Individual results will vary, with some obtaining no benefit. Comparisons use results from separate published trials involving different populations and protocols. They are not direct head-to-head randomized comparisons.
Effect distribution
Qualifying comparisons, plotted.
Core exceeded 34 of 36
NOVOS Core 6.1 mmHg
Green dots are statistically significant competitor results. Gray dots are qualifying comparisons with no significant demonstrated effect. Yellow dots mark the average across multiple studies of the same ingredient. The dashed orange line is the NOVOS Core benchmark. Separate published trials. Not direct head-to-head randomization.
Improving one marker has been achieved. All 3, to this degree, is a first.
| Supplement | Healthy blood pressure | Arterial flexibility | Endothelial function |
|---|---|---|---|
| NOVOS Core | 3 of 3Effect matched or exceeded the Core magnitude among successful trials | 3 of 3Effect matched or exceeded the Core magnitude among successful trials | 3 of 3Effect matched or exceeded the Core magnitude among successful trials |
| Omega-3 / Fish oil | 2 of 3At least half of Core's effect magnitude | 1 of 3A smaller demonstrated effect | 2 of 3At least half of Core's effect magnitude |
| Beetroot / Nitrate | 2 of 3At least half of Core's effect magnitude | Tested, but no statistically significant effect demonstrated | 2 of 3At least half of Core's effect magnitude |
| Magnesium | 1 of 3A smaller demonstrated effect | 2 of 3At least half of Core's effect magnitude | Tested, but no statistically significant effect demonstrated |
| Folate | Tested, but no statistically significant effect demonstrated | Not evaluated in the qualifying dataset | 1 of 3A smaller demonstrated effect |
| L-Arginine | 1 of 3A smaller demonstrated effect | Tested, but no statistically significant effect demonstrated | 1 of 3A smaller demonstrated effect |
| Garlic | 1 of 3A smaller demonstrated effect | Tested, but no statistically significant effect demonstrated | Tested, but no statistically significant effect demonstrated |
| L-Carnitine | 1 of 3A smaller demonstrated effect | Not evaluated in the qualifying dataset | Not evaluated in the qualifying dataset |
| Spirulina | 1 of 3A smaller demonstrated effect | Not evaluated in the qualifying dataset | Tested, but no statistically significant effect demonstrated |
- 1 bars
- A smaller demonstrated effect
- 2 bars
- At least half of Core's effect magnitude
- 3 bars
- Effect matched or exceeded the Core magnitude among successful trials
- X
- Tested, but no statistically significant effect demonstrated
- –
- Not evaluated in the qualifying dataset
Core was the only supplement in the analysis to show a full-strength profile across all three measures.
How we built the benchmark
- Search pool
- 3,388 PubMed records.
- Qualifying RCTs
- 147.
- Unique competitor studies
- 142.
- Study-marker comparisons
- 171.
- Strict like-for-like set
- 55 fasted comparisons.
- Biomarkers
- Systolic blood pressure, arterial flexibility and endothelial function.
- Analysis
- Between-group, placebo-adjusted effects.
- Null results
- Retained.
- Important limitation
- The comparison combines results from separate studies involving different populations and protocols. It is not a direct randomized head-to-head trial.
One formulation.
Three independent vascular measures.
Randomized human evidence.
Results uncommon in supplement research.
Delivers vascular benefits rarely seen with dietary supplements and nutrition.
Sets a new benchmark for what a longevity supplement can achieve in humans.
Cardiovascular health was the test system. Longevity was the design objective.
NOVOS Core was not formulated as a conventional heart supplement.
It was built as a coordinated multi-pathway formulation designed around the biology of aging.
Cardiovascular physiology was selected as the first human system to measure because it is sensitive to age-related change and can be evaluated with validated functional endpoints.
Provides nutritional support for biological systems predictive of lifespan and healthspan.
The cardiovascular trial demonstrates functional engagement of one major aging-related physiological system in humans. It does not mean cardiovascular biology is the only system Core was designed to support.
The longevity foundation
Clinically studied
NOVOS Core
The human trial measured one physiological system. Core was designed around twelve mechanisms of aging.
A formula is not simply the sum of its ingredients.
A modern longevity stack often begins by finding several individually promising compounds and assuming their effects will add together. That assumption is not always correct.
Researchers studying combinations of longevity compounds in lifespan models have found:
- synergistic combinations (8% of combinations)
- additive combinations (31% of combinations)
- neutral combinations (8% of combinations)
- combinations that performed worse than the strongest individual intervention (38% of combinations)
- combinations that negatively affected lifespan in the model (15% of combinations)
Preclinical model
Synergy should be tested, not assumed.
That is why NOVOS studies Core as a complete formulation.
Stack
- Ingredient A
- Ingredient B
- Ingredient C
- Ingredient D
- Ingredient E
Promising separately.
System
- Hallmarks
- Physiology
- Finished-formula research
Designed together. Studied together.
NOVOS Core was built as a system by carefully evaluating its bio pathways with a team of researchers, rather than just stacking together trendy ingredients.
Preclinical
Longevity research still has to ask the lifespan question.
Aged animal modelComplete Core formulationLifespan and healthspan outcomes
Statistically significant results on lifespan and healthspan in aged animal models were observed.
Animal lifespan studies can test long-duration whole-organism outcomes that cannot practically be studied across a human lifespan. They do not establish that NOVOS Core extends human lifespan.
Show me the science: aged-animal lifespan
Study type: aged-animal lifespan and healthspan research using the complete Core formulation.
Measured: median lifespan plus functional health measures.
Finding: where currently cleared for commercial display, an 18% greater median lifespan versus control was reported.
Does not prove: human lifespan extension or disease prevention.
Biological pace of aging
Can we measure how quickly someone is aging?
DunedinPACE is designed to estimate biological Pace of Aging from epigenetic patterns. In a preliminary observational NOVOS study, participants used Core plus Boost and completed biological-aging testing over time.
73%
showed a measurable reduction in Pace of Aging
Small observational study. No placebo group. Preliminary evidence. DunedinPACE is a research-informed biological-aging biomarker, not a clinical disease outcome.
A longevity routine still has to fit real life.
NOVOS Core also provides short term benefits
- Energy
- Sleep
- Calm focus
- Mood
- Skin
Longevity matters later. The routine still has to make sense today.
Daily experience positioning reflects ingredient-level research and customer reporting. It does not mean every subjective benefit was measured in the Core randomized study.
81% of surveyed NOVOS customers reported feeling a difference within two weeks across six areas of wellbeing.
Areas surveyed: energy, sleep, cognition, mood, skin and overall wellbeing.
Self-reported customer survey. Not a randomized clinical trial. Individual results vary.
The people behind the formulation
Built with people who study why we age.
Dr. George Church, PhD
Harvard Medical School and MIT
Genomics pioneer whose laboratory studies the genetics of aging and reprogramming.
Dr. Pamela Maher, PhD
Salk Institute and University of British Columbia
Neurobiologist studying plant compounds, cellular stress resilience and brain aging.
Dr. J. Pedro de Magalhaes, PhD
University of Birmingham
Biogerontologist researching the comparative biology and genetics of lifespan.
Dr. Diogo Barardo, PhD
NOVOS Head of R&D
Longevity researcher focused on multi-pathway formulation design and evaluation.
Science that clinicians enthusiastically recommend.
2,000+
verified MDs & clinicians recommend NOVOS
Clinician status is confirmed through the NOVOS clinician-verification framework.
Available at
Mayo Clinic Store • Bumrungrad International Hospital • Remedy Place • Erewhon • Select FourSeasons & Equinox
Retail availability is not an institutional medical endorsement. Individual physician quotes should use exact approved wording with name and affiliation.
Supplements are only one part of longevity.
NOVOS Life turns broader longevity science into personalized daily recommendations spanning products, nutrition, exercise, sleep and lifestyle.
Learn
NOVOS science and education
Support
Core, Boost, Vital, Bar
Measure
NOVOS Age
Personalize
NOVOS Life
Built for more than selling supplements.
NOVOS is a Public Benefit Corporation with a stated mission centered on longevity science, healthspan and accessible longevity education.
Why NOVOS is a Public Benefit CorporationPart of the professional longevity ecosystem.
NOVOS participates in the Longevity Biotechnology Association and the Healthy Longevity Medicine Society. This is an organizational credibility signal, not product efficacy evidence.
Different supplements solve different problems.
Multi-pathway longevity foundation
NOVOS Core
Designed around the Hallmarks. Complete formulation studied.
What should you compare before buying?
What are you trying to do?
Cover nutritional gaps
High-quality diet and a multivitamin
Support NAD+
NOVOS Boost
Target one longevity pathway
A single ingredient
Build a broad longevity foundation
NOVOS Core
Support organ systems
NOVOS Vital
Improve daily nutrition
NOVOS Bar
Measure biological aging
NOVOS Age
Brands within each category vary substantially. The table describes common category positioning and is not a claim about every product.
What we know. What we do not.
What we know
- Core's complete formulation has been evaluated in randomized human research.
- The study showed beneficial effects over placebo across multiple independent functional measures associated with healthspan and lifespan.
- Core extended aged animal lifespan.
- Core plus Boost have preliminary research showing reduced epigenetic pace of aging.
- Core has in vitro research showing improvements in DNA protection, cellular senescence, oxytosis/ferroptosis, and cellular inflammation.
- The complete formula is patent-pending, and 81% of users report subjective benefits after two weeks of use.
What we do not know yet
- Whether preliminary biological-age findings will replicate in larger controlled studies.
- Whether the aged animal lifespan extension translates to humans.
- Whether preliminary biological-age findings will replicate in larger placebo-controlled studies.
- The magnitude of any long term human lifespan and healthspan effect.
- If the improvements in skin firmness will replicate in larger placebo-controlled studies.
- Which other organ systems the NOVOS Core formula may impact (e.g., brain, liver, kidneys, etc.).
Good longevity science shows the limits too.
Show me the science: cardiovascular RCT
Study type: randomized, double-blind, placebo-controlled human study.
Who was studied: adults aged 40 and over across six months.
Measured: endothelial function, arterial flexibility and healthy blood-pressure support.
Finding: significant beneficial effects over placebo on multiple functional vascular measures.
Does not prove: prevention or treatment of cardiovascular disease or human lifespan extension.
The best supplement cannot rescue the rest of your lifestyle.
Longevity still depends heavily on:
- Exercise
- Nutrition
- Sleep
- Metabolic health
- Prevention
- Stress management
- Social connection
NOVOS products are designed to complement those fundamentals.
Longevity should be more than a claim.
Research should go beyond individual ingredients.
A formula should be studied as the complete formula.
Human studies should measure actual function.
Most companies market supplements.
NOVOS runs a longevity research program.
These statements have not been evaluated by the Food and Drug Administration. These products and information are not intended to diagnose, treat, cure, or prevent any disease.